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Abstract
 .Treatment of Parkinson patients with L-DOPA 3,4-dihydroxy-L-phenylalanine leads to endproduct inhibition of tyrosine
hydroxylase, the key enzyme in dopamine biosynthesis and the enzyme needing tetrahydrobiopterin and iron as cofactors.
To overcome this problem an alternative treatment was investigated which attempted to stimulate endogenous dopamine
 .biosynthesis. Incubation of rat PC 12 cells with NADH b-nicotinamide adeninedinucleotide leads to increased dopamine
production. We investigated the possibility that this increase of dopamine biosynthesis was due to stimulation of quinonoid
dihydropteridine reductase, the enzyme which recycles the inactive dihydrobiopterin to the active tetrahydrobiopterin. The
experiments showed that whereas NADH is able to increase dopamine production in PC 12 cells rat phaeochromocytoma
.cells, clone PC 12 up to three-fold, no influence is exerted by NADH on pteridine metabolism; neither are tetrahydro-
biopterin concentrations nor the de novo-biosynthesis of pteridines from guanosine triphosphate altered by NADH. Further
no influence of NADH on protein de novo synthesis of quinonoid dihydropteridine reductase was observed. However,
NADH was able to directly increase the catalytic activity of this enzyme. Our results suggest that the stimulation of
dopamine biosynthesis by NADH is due to more rapid regeneration of quinonoid dihydrobiopterin to tetrahydrobiopterin.
Keywords: Parkinson’s disease; Dopamine biosynthesis; NADH; Quinonoid dihydropteridine reductase; Tetrahydrobiopterin; PC 12 cell;
 .Rat
1. Introduction
Parkinson’s disease is characterized by a func-
tional deficit of the neurotransmitter dopamine in the
striatum and a loss of dopaminergic cells in the zona
compacta of the substantia nigra. The result is a
diminished presence of the tyrosine hydroxylase, the
w xkey enzyme in dopamine biosynthesis 1,2 , an en-
zyme which needs tetrahydrobiopterin as cofactor.
) Corresponding author. Fax: q43 316 3809610.
Investigations regarding the localisation of tetrahy-
drobiopterin have suggested that it is concentrated in
w xnigrostriatal dopaminergic neurons 3,4 . The concen-
w xtration of the cofactor tetrahydrobiopterin 5–8 as
well as the activity of the DHPR quinonoid dihy-
.dropteridine reductase , the enzyme which recycles
the inactive quinonoid dihydrobiopterin to tetrahydro-
biopterin, are diminished, too, in the basal ganglia of
w xParkinson patients 9 .
 .Clinical experiments using tetrahydro bio pterin
w xhave been contradicting: Nagatsu et al. 10 and
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w xNichol et al. 11 demonstrated that oral administra-
tion of tetrahydrobiopterin to Parkinson patients does
not lead to improvement of clinical symptoms, be-
cause tetrahydrobiopterin is not able to cross the
w xblood brain barrier. However, Kaufmann et al. 12
reported an increased content of tetrahydropterin in
CSF after administering tetrahydropterin peripherally
and suggested that the administration of the tetrahy-
dropterin may prove to be a treatment not only for
the impaired peripheral phenylalanine metabolism,
but also for neurologic disorders of the variant forms
of hyperphenylalaninaemia. Tetrahydrobiopterin re-
placement therapy has also been tried with only
limited success in several neuropsychiatric diseases
w xlike endogenous depression 13 and familial dystonia
w x14–16 . Further attempts to increase intraneuronal
tetrahydrobiopterin content through intracerebral in-
jections of tetrahydrobiopterin in rats have been suc-
w xcessful 17 . Systemic administration of tetrahydro-
biopterin to rats increases brain tetrahydrobiopterin
w x18 but not to levels sufficiently high to enhance
w xbrain biogenic amine synthesis 19 . Anastasiadis et
w xal. 20 reported a linear and concentration dependent
uptake of tetrahydrobiopterin in cultured PC12 cells.
Although there was only one clinical case of Parkin-
w xson’s disease, Kondo et al. 21 reported that oral
administration of tetrahydropterin improved the clini-
cal symptoms of Parkinson’s disease.
On the other hand, dihydropteridine reductase is
coupled to the NADqrNADH redox system. With
this knowledge in mind we studied dopamine and
tetrahydrobiopterin biosynthesis under the influence
of NADH in vitro in rat phaeochromocytoma cells
 .clone PC 12 , which have a metabolism comparable
to the substantia nigra nerve cells they develop from
.the same germ layer .
These experiments were performed firstly in order
to find out whether NADH is able to stimulate en-
dogenous dopamine biosynthesis. If this would be the
case, the well known endproduct inhibition of L-
DOPA which is used as classical medication in
w xParkinson patients 22 , could be eliminated. If the
endogenous L-DOPA biosynthesis could be stimu-
lated in addition to the already increased activity of
the residual tyrosine hydroxylase in the remaining
neuronal cells of basal ganglia, L-DOPA would not
be produced in such a surplus that the endogenous
activity of tyrosine hydroxylase could be influenced.
Secondly, the influence of NADH on tetrahydro-
biopterin de novo synthesis was tested by measuring
the activity of the key enzyme of pteridine biosynthe-
 .sis, e.g., GTP-cyclohydrolase I E.C. 3.5.4.16 and
the concentrations of biopterin itself. Further the
influence of NADH on protein de novo synthesis of
 .the DHPR E.C. 1.6.99.7 was investigated. Finally, a
possible effect of NADH on catalytic activity of
DHPR was studied.
2. Materials and methods
PC 12 cells were cultured in RPMI medium
Roswell Park Memorial Institute, RPMI 1640 from
.Boehringer, Mannheim, Germany with 10% horse
serum and 5% fetal calf serum in 75 cm2 tissue
 .culture flasks Szabo, Vienna, Austria at 378C in 5%
CO –95% air and 95% humidity. The cells were2
cultured as monolayers. When the experiments were
started, the PC 12 cells were in a stationary phase
referring to growth. This was achieved by changing
the medium during cultivation every second day. The
time interval between first and last recultivation be-
fore the experiment was always the same. 48 h before
starting the experiment the cells were centrifuged at
low speed, the medium discarded and 1P107 cells
were recultivated in new culture flasks with 20 ml
fresh medium. On the day of carrying out the experi-
ments, the cells were washed with RPMI medium
 .without horse and calf serum and subsequently each
of 4P107 cells were incubated for 0, 4, 8 or 24 h
parallely with 15 ml RPMI medium alone or together
with 400 mg NADHrml medium. After incubation
the medium was collected and stored until analysis at
y708C. The dopamine content in the medium was
determined, after deproteinisation with 0.4 M per-
chloric acid, by HPLC high performance liquid chro-
. w xmatography using electrochemical detection 20,23 .
The Coulochem electrochemical detector Model 5100
 .A ESA, Wiggins Avenue, Bedford, MA was used
in connection with a high sensitivity analytical cell
 .ESA-Model 5011 . Separation was achieved by a
catecholamine HR-80 column 4.6P80 mm, packed
with the micron C 18 stationary phase and purchased
.from ESA with ESA mobile phase for catechol-
amines.
The cells were washed with saline, the cell pellet
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resuspended in 1 mM dithioerythrol and 0.1 mgrml
Pefabloc and subsequently frozen in liquid nitrogen
to break up the cells. For analysis the cells were
thawed and homogenized UltraThurax, Model 1510,
.B. Braun, Melsungen, Germany and subsequently an
aliquot of these cell extracts was freed from low
molecular weight compounds by chromatography on
small Sephadex G-25 desalting columns NAP-5
 .Pharmacia, Uppsala, Sweden using the assay buffer
as eluent, which contained 0.1 M 2-amino-2-
hydroxymethyl-1,3-propandiol hydrochloride Tris-
.HCl , pH 7.8; 5 mM EDTA, 0.3 M KCl and 10%
 .vrv glycerol.
In these purified cell extracts GTP-cyclohydrolase
I was estimated according to the method of Viveros
w xet al. 24 . An aliquot of the obtained protein fraction
was incubated with 2 mM guanosine triphosphate
 .GTP for 90 minutes at 378C in the dark. The
reaction was terminated by addition of 0.1 M final
.concentration HCl and the 7,8-dihydroneopterin
triphopsphate oxidized to neopterin phosphates by
0.01 M KIP I by incubation for 1 h in the dark at2
room temperature. Insoluble material was removed
 .by centrifugation 10 000=g, 2 min , the iodine
excess destroyed by 0.01 M ascorbic acid. After
neutralisation, using NaOH, the phosphates were
cleaved by alkaline phosphatase for one hour at 378C
in the dark. Afterwards neopterin was determined by
HPLC Waters 474 Scanning Fluorescence Detector,
.Waters, Vienna, Austria using fluorescence detection
 .353 nm excitation, 438 nm emission wavelengths .
As analytical column a ready-to-use cartridge was
employed Hibar LiChroCart, 125=4 mm, E. Merck,
.Darmstadt, Germany , packed with 7 mm reversed
 .phase C-18 material LiChroSorb, RP 18, E. Merck .
For protection of the analytical column, a guard
cartridge was used Hibar LiChroCart, 4=4 mm, E.
.Merck packed with the same material.
Aliquots of sonicated cell homogenates were oxi-
dized in acidic and in alkaline solution. During alka-
line oxidation only dihydrobiopterin is converted into
biopterin, tetrahydrobiopterin undergoes side chain
loss and conversion to compounds different from
biopterin. Alkaline oxidation must therefore be car-
ried out very quickly by addition of NaOHP I 1 N2
NaOH with 0.1 M I solved in 0.25 M KI in a2
.mixture of 1:1 and incubation for 1 h in the dark at
room temperature. If one carries out the alkaline
oxidation step not quickly enough, dihydrobiopterin
may be formed from tetrahydrobiopterin by air oxida-
tion; the analysis in that case would suggest too low
tetrahydrobiopterin values. After incubation 1 N HCl
is added, unsoluble material centrifuged and the io-
dine excess destroyed by 0.1 M ascorbic acid. During
acid oxidation dihydro- and tetrahydrobiopterin are
oxidized by 0.01 M iodine solution 1 N HCl with
.0.1 M I in 0.25 M KI in a mixture of 1:1 to the2 2
w xfluorescent biopterin 25 . After acidic or alkaline
oxidation of aliquots of sonicated cell homogenate,
biopterin was measured by HPLC, using fluorescence
detection and the same chromatographic conditions
as for determination of neopterin which of course
.has a different retention time . Thus, the amount of
tetrahydrobiopterin is estimated by subtracting the
biopterin concentration found after alkaline oxidation
from the value obtained after acidic oxidation.
In another aliquot of sonicated cell homogenate
DHPR activity was measured. The principle of the
assay is the reaction of tetrahydrobiopterin formed in
the DHPR reaction with dichlorophenol-indophenol
to yield quinonoid dihydrobiopterin, which is again
substrate for DHPR. By this redox reaction, the blue
colour of dichlorophenol-indophenol disappears in
proportion to the DHPR activity. The assay endcon-
centration was as following: 0.05 M Tris, pHs7.3;
10 mM tetrahydrobiopterin; 0.1 mM NADH, 0.002–
0.05 U DHPR and 0.1 mM dichlorophenol indophe-
nol. Absorbance decrease was measured at 620 nm
and 258C during the first ten minutes of the reaction
after addition of dichlorophenol indophenol to the
incubation assay. To test whether the enzymatic ac-
tivity of DHPR can be increased by higher concentra-
tions of NADH than used in the classical assay, the
DHPR determination was performed in further exper-
iments by adding 1000, 2000, and 3000 mg NADH to
the assay in the cuvette for three replicas.
NADH b-nicotinamide adenine dinucleotide, re-
.duced form, disodium salt was purchased from
Boehringer, dopamine, 2,6-dichlorophenol-
 indophenol, sodium salt 2,6-dichlor-N- 4-hydroxy-
. .phenyl -1,4-benzochinonimin, sodium salt and
 .dithioerythritol from Sigma St. Louis, MO, USA ,
 .6R -5,6,7,8-tetrahydro-L-biopterin dihydrochloride
 .from Schirks Jona, Switzerland . Pefabloc and all
other reagents were obtained from E. Merck and were
of reagent grade.
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Statistical evaluation of results was performed by
 .two-way analysis of variance ANOVA . Here, con-
centrations of dopamine and tetrahydrobiopterin, and
activity of GTP-cyclohydrolase I were used as depen-
dent variables. The effects of the factors NADH
 . absence versus presence and incubation time 4, 8,
.24 h were determined. For analysis of the effect of
NADH on DHPR activity ANOVA for repeated mea-
surements was used. We employed program
BMDP2V, BMDP Statistical Software Cork, Ire-
.land .
3. Results
As shown in Fig. 1 the dopamine content in the
culture medium increased up to threefold after incu-
bating 4P107 cells with 400 mg NADHrml medium,
compared with controls. By two-way ANOVA, both
incubation time and NADH were shown to be highly
significant factors determining dopamine concentra-
 .tion P-0.0001 for both variables .
As determined by alkaline and acidic oxidation of
cell extracts, all the biopterin we found in the cell
homogenate occurred in the tetrahydro form details
.not shown . Whereas incubation time significantly
influenced tetrahydrobiopterin levels P-0.0001;
.  .ANOVA , no significant difference Ps0.72 was
seen between controls and cells incubated with 400
 .mg NADHrml medium Fig. 2 .
 .Similarly lack of influence of NADH Ps0.88
 .but significant effect of incubation time P-0.0001
Fig. 1. Dopamine concentrations in ngrml medium mean and
. 7error bars SD after incubation of 4P10 PC 12 cells in 15 ml
 .RPMI medium without NADH white bars and with 400 mg
 .NADHrml black bars for 0, 4, 8 and 24 h.
Fig. 2. Tetrahydrobiopterin concentration in nmrl cell ho-
 . 7mogenate means and error bars SD after incubation of 4=10
 .PC 12 cells in 15 ml RPMI medium without NADH white bars
 .and with 400 mg NADHrml black bars for 0, 4, 8, and 24 h.
Fig. 3. Activity of GTP-cyclohydrolase I in nmol neopterinrl
 .means and error bars SD in purified cell extracts after incuba-
tion of 4P107 PC 12 cells in 15 ml RPMI medium without
 .  .NADH white bars and with 400 mg NADHrml black bars for
0, 4, 8 and 24 h.
Fig. 4. DHPR activity in sonicated cell homogenates after incuba-
tion of 4P107 PC 12 cells in 15 ml RPMI medium without
 . NADH white bars with SD and with 400 mg NADHrml black
.bars with SD for 0, 4, 8 and 24 h.
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Fig. 5. DHPR activity after further addition of 0 or 1000 mg
NADH directly to 1 ml of PC 12 cell homogenate to the classical
assay and subsequent measurement of enzymatic activity de-
crease of absorbance at 620 nm during the first 4 min of the
.assay .
were observed for the activity of GTP-cyclohydrolase
 .I Fig. 3 .
Nearly the same result was obtained by measuring
the activity of DHPR after having incubated the cells
with or without NADH. Thus we found no evidence
for an influence of NADH on de novo synthesis of
 .DHPR Fig. 4 . To investigate whether the enzymatic
activity of DHPR can be stimulated directly by
NADH, different amounts of NADH were added to
the cell homogenate to the classical assay in the
cuvette. Addition of 1000 mg NADH to 1 ml ho-
mogenate increased absorbance change significantly
 .Ps0.015; ANOVA for repeated measurements
 .Fig. 5 . Addition of higher concentrations of NADH
 .2000 or 3000 mg, data not shown in detail led to a
saturation of this substance in the assay; only a small
additional absorbance change was observed in com-
parison to the 1000 mg value.
4. Discussion
This study confirms that NADH is able to stimu-
late endogenous dopamine biosynthesis. The signifi-
cant increase of dopamine concentration in the cul-
ture supernatants after incubation of the cells with
400 mg NADHrml shows that NADH influences the
activity of the key enzyme tyrosine hydroxylase. In
previous experiments we found that the activity of
tyrosine hydroxylase is stimulated up to 75% by 400
w xmg NADHrml incubation medium 26 . However we
are aware of the possibility that the change of
dopamine concentration in the incubation medium is
not only a function of the activity of tyrosine hydrox-
ylase, it may also reflect synthesis, transport, release
and metabolism changes in other pathways. Further
the increase of dopamine concentration could be due
to the possibility of the inhibitory effect on dopamine
autooxidation by tetrahydrobiopterinrDHPR-media-
ted antioxidation system. Shen R.S. reported that
tetrahydrobiopterin, in combination with NADH and
DHPR, acted as an antioxidation system during
dopamine autoxidation and this antioxidation system
required the simultaneous presence of tetrahydro-
w xbiopterin, NADH and DHPR 27 . PC12 cells are
susceptible to toxicity caused by xanthinerxanthine
oxidase, hydrogen peroxide and dopamine. Shen et
al. also reported that the toxicities of these agents
were reduced by the simultaneous presence of tetra-
hydrobiopterin, NADH and DHPR — tetrahydro-
w xbiopterin antioxidation system 28 .
We indicate that the stimulating effect of NADH
on dopamine biosynthesis is mainly based on supply-
ing the tyrosine hydroxylase with sufficiently tetrahy-
drobiopterin cofactor by speeding up the recycling
pathway from dihydrobiopterin to tetrahydrobiopterin
via the DHPR system. A further argument that the
increased dopamine concentration is due to increased
activity of tyrosine hydroxylase is, that only NADH
is offered to the incubation medium of PC12 cells in
surplus. If the endogenous concentrations of tetrahy-
drobiopterin, NADH and DHPR of PC12 cells would
be sufficiently to reduce the susceptibility of these
cells to toxicity caused by xanthinerxanthine oxidase
and hydrogen peroxide, the PC12 cells incubated as
controls without NADH should be able to produce
dopamine to the same extend as PC12 cells incubated
with NADH. Besides we found that whether the
quantity of DHPR enzyme protein is influenced by
NADH nor the absolute concentration of tetrahydro-
biopterin cofactor, which is in all probability con-
sumed by the tyrosine hydroxylase immediately.
Previous studies have shown that the GTP cyclo-
hydrolase I activity in mononuclear blood cells from
patients with juvenile Parkinsonism is normal as
w xcompared to healthy controls 29 . This indicates that
the decreased dopamine level in the basal ganglia of
juvenile Parkinsonism is not due to decreased activity
of GTP cyclohydrolase I, the enzyme responsible for
the de novo synthesis of the tetrahydrobiopterin co-
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factor of tyrosine hydroxylase. The question remains
why the concentration of the tetrahydrobiopterin co-
factor is diminished in the striatum and cerebospinal
fluid of Parkinson patients as previous studies have
w xdemonstrated 5–8 .
Under normal physiological conditions, this re-
duced form constitutes approximately 80–90% of
w xtotal biopterin in tissues 30,31 .
w xAnastasiadis et al. 20 also measured cate-
cholamine levels in PC 12 cells following exposure
to tetrahydrobiopterin They found that the intra-
cellular levels of dopamine and L-DOPA were signif-
icantly increased following incubations with tetrahy-
drobiopterin. Concentrations of norepinephrine, dihy-
droxyphenyl acetic acid and homovanillic acid were
not changed by tetrahydrobiopterin in either the intra-
cellular or extracellular compartments. These results
demonstrate that tetrahydrobiopterin is actually enter-
ing the PC 12 cells, where it is interacting with
tyrosine hydroxylase to enhance L-DOPA and
dopamine production. Further they suggest that the
uptake of tetrahydrobiopterin is a saturable process,
because neither glucose nor sodium could enhance it.
Moreover, the uptake of tetrahydrobiopterin into PC
12 cells becomes asymptotic over time. After twenty
minutes incubation time of PC 12 cells together with
tetrahydrobiopterin it appeared that the intracellular
concentration had reached equilibrium with the extra-
cellular concentration.
In our experiments the concentration of tetrahydro-
biopterin as well as the activity of GTP-cyclohydro-
lase I in the PC 12 cells were not influenced by
NADH. These findings suggest that NADH is not
able to stimulate the de novo synthesis of tetrahydro-
biopterin from guanosine triphosphate.
Further, lack of influence of incubating the cells
with NADH on DHPR de novo synthesis was found.
We thought that NADH perhaps is able to force
mitochondrial oxidative phosphorylation and further
its enzyme systems could be able to influence gene
expression for de novo synthesis of DHPR enzyme
protein, because during mitochondrial oxidative phos-
 .phorylation four enzymes complexes I–IV transport
 .electrons from NADH or succinate to oxygen and
pump protons out of the mitochondria to form an
electrochemical gradient. The fifth enzyme complex
.V uses the electrochemical gradient to synthesize
 .adenosine triphosphate ATP from adenosine
 .diphosphate ADP . These five enzymes are assem-
bled from 13 polypeptides coded by the mitochon-
drial DNA and approximately 50 polypeptides coded
by the nuclear DNA. In addition the mitochondrial
 .DNA codes two ribosomal ribonucleic acids RNA
and 22 transfer RNAs necessary for mitochondrial
w x w xDNA gene expression 32,33 . As Parker et al. 34
w xand Shapira et al. 35 described complex I defects in
platelets and substantia nigra from patients with
Parkinson’s disease, NADH could be effective at this
site. But the increase of enzymatic activity after
addition of higher amounts of NADH directly to the
enzyme assay suggests that NADH increases
dopamine biosynthesis simply by its reductive capac-
ity via enhancing the recycling of quinonoid dihydro-
biopterin to tetrahydrobiopterin.
The comparison of these studies in PC12 cells to
what may occur in Parkinson neurons is unclear. But
previous studies have shown that NADH is able to
stimulate dopamine biosynthesis in Parkinsonian pa-
w xtients too 36,37 . Measurement of L-DOPA and
dopamine concentrations in the brain, in particular in
substantia nigra in Parkinsonian patients before and
after NADH treatment is impossible for the time
being. Therefore homovanillic acid, the metabolic
product of dopamine was measured in the urine in
these studies, and the level of this substance in-
creased after NADH treatment parallely to the im-
provement in disability.
Summarizing our results, we found no explanation
for the well established stimulation of dopamine
biosynthesis by NADH other than the cosubstrate
function of this compound in the DHPR reaction.
Since this direct action of NADH was found in
PC12 cells in vitro, further experiments are scheduled
to inquire into the details of NADH effects upon
intact cells.
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